Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma

This study aimed to compare the efficacy of nimotuzumab (Nimo) versus cetuximab (C225) plus concurrent chemoradiotherapy (CCRT) in locally advanced esophageal squamous cell carcinoma (LA-ESCC). A total of 95 patients with LA-ESCC were retrospectively reviewed, including 65 in Nimo and 30 in C225. Th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Biol Ther
Autori principali: Jing, Wang, Yan, Weiwei, Liu, Yuguo, Li, Ji, Yu, Jinming, Zhu, Hui
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2019
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606014/
https://ncbi.nlm.nih.gov/pubmed/30983494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1598760
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi